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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.06.016Objective: Distinction of lymph node stations is one of the most crucial topics still not
entirely resolved by many lung cancer surgeons. The nodes around the junction of the
hilum and mediastinum are key points at issue. We examined the spread pattern of
lymph node metastases, investigated the prognosis according to the level of the involved
nodes, and conclusively analyzed the border between N1 and N2 stations.
Methods: We reviewed the records of 604 consecutive patients who underwent
complete resection for non–small cell lung carcinoma of the lower lobe.
Results: There were 390 patients (64.6%) with N0 disease, 127 (21.0%) with N1, and
87 (14.4%) with N2. Whereas 11.3% of patients with right N2 disease had skip
metastases limited to the subcarinal nodes, 32.6% of patients with left N2 disease had
skip metastases, of which 64.2% had involvement of N2 station nodes, except the
subcarinal ones. The overall 5-year survivals of patients with N0, N1, and N2 disease
were 71.0%, 50.8%, and 16.7%, respectively (N0 vs N1 P  .0001, N1 vs N2, P 
.0001). Although there were no significant differences in survival according to the side
of the tumor among patients with N0 or N1 disease, patients with a left N2 tumor had
a worse prognosis than those with a right N2 tumor (P  .0387). The overall 5-year
survivals of patients with N0, intralobar N1, hilar N1, lower mediastinal N2, and upper
mediastinal N2 disease were 71.0%, 60.1%, 38.8%, 24.8%, and 0%, respectively.
Significant differences were observed between intralobar N1 and hilar N1 disease (P
.0489), hilar N1 and lower mediastinal N2 disease (P  .0158), and lower and upper
mediastinal N2 disease (P  .0446). Also, the 5-year survivals of patients with
involvement up to station 11, up to station 10, and up to station 7 were 41.4%, 37.9%
and 37.7%, respectively (difference not significant).
Conclusions: N1 and N2 diseases appeared as a combination of subgroups: intralo-
bar N1 disease, hilar N1 disease, lower mediastinal N2 disease, and upper medias-
tinal N2 disease. Interestingly, the survivals of patients with involvement up to
interlobar nodes (station 11), main bronchus nodes (station 10), and subcarinal
nodes (station 7) were identical. These data constitute the basis for a larger
investigation to develop a lymph node map in lung cancer.
In non–small cell lung cancer, metastasis to lymph nodes, the N factor, isone of the most important determinants of prognosis.1-5 Accurate lymphnode staging is therefore imperative to select therapeutic strategies. Cur-rently some variations of the lymph node map can be found, and thusconsiderable discordance exists regarding the designation of sites amongdoctors in the United States, Europe, and Japan,6 which has been causing
confusion. Understandably, the survival of patients with N1 disease is between that
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considered, because N1 lymph nodes are anatomically po-
sitioned upstream from N2 nodes. However, both N1 and
N2 disease represent heterogeneous groups with variable
survivals.7,8 In each case, the involved nodal levels could
probably have different influences on patients’ survival.
One of the most significant problems concerning lymph
node involvement under debate among thoracic oncologists
is the definition of the borderline between N1 and N2
stations, which must be absolutely clarified, because other-
wise discordance could distort stages reported in different
studies. More importantly, in the clinical setting, the poten-
tial therapeutic strategies for patients with N1 and N2 dis-
ease differ remarkably. In other words, it is difficult to deal
with interface nodes at the junction of the hilum and medi-
astinum, which are around the main bronchus. We should
direct our efforts toward defining the border more precisely
and reach consensus on the basis of up-to-date evidence.
We reviewed the records of patients with completely
resected non–small cell lung cancer to examine the clinical
features of lymph nodal involvement. The purposes of this
study were to investigate the pattern of lymph node metas-
tases, to analyze survivals of patients according to the level
of nodal involvement, and to bring up an unsolved issue on
the anatomic border between N1 and N2 stations. To make
the anatomic stream of lymph nodes clearly understandable,
patients in this study were limited to those with a primary
lesion originating from the lower lobe.
Material and Methods
Between July 1984 and December 2003, a total of 604 consecutive
TABLE 1. Pattern of N2
Right lung Left lung
Total 44 43
Only lower mediastinum 29 33
Skip of N1, station 7 5 5
Skip of N1, station 8 0 3
Skip of N1, station 9 0 2
Skip of N1, stations 7 and 8 0 2
Skip of N1, stations 7 and 9 0 1
N1 and station 7 15 10
N1 and station 8 1 2
N1 and station 9 0 2
N1 and stations 7 and 8 4 5
N1 and stations 7 and 9 0 1
N1 and stations 8 and 9 1 0
N1 and stations 7, 8, and 9 3 0
Upper mediastinum 15 10
Skip of N1, Botallo’s node 0 1
N1 and upper mediastinum 2 4
N1, station 7, and upper mediastinum 13 5
Data represent numbers of patients.patients operated on for primary non–small cell carcinoma in the
826 The Journal of Thoracic and Cardiovascular Surgery ● Aprilower lobes of the lungs had pathologic confirmation of complete
removal with systematic nodal dissection of the hilum and medi-
astinum. Approval of the institutional review board was obtained
to collect these patients’ data in a secure database and report their
outcomes. Histologic type of the tumor was determined according
to the World Health Organization classification. Patients with
low-grade malignancy of the lungs, such as carcinoid, were ex-
cluded. Staging was determined according to the international
TNM staging system.1 All dissected lymph nodes were patholog-
ically examined and classified according to anatomic location by
Naruke and colleagues’ numbering system.2 Patients who had been
subjected to induction chemoradiotherapy or adjuvant therapy
were excluded. For staging, all patients underwent a physical
examination; chest radiography; computed tomography of the tho-
rax, brain, and upper abdomen; bone scintigraphy; and bronchos-
copy. After surgery, the patients were examined at 3-month inter-
vals for 5 years and thereafter at 1-year intervals in general. The
evaluations included physical examination, chest radiography, and
tumor markers. Moreover, chest, abdominal, and brain computed
tomographic scans and a bone scintiscan were carried out each
year.
One hundred sixty-five patients were female and 439 were
male, ranging in age from 32 to 83 years with a median of 67
years. The histologic classification was adenocarcinoma in 293
patients, squamous cell carcinoma in 285, adenosquamous carci-
noma in 13, and large cell carcinoma in 13. There were 266
patients with left-sided tumors and 338 with right-sided tumors.
One hundred ninety-seven patients had pathologic stage IA dis-
ease, 164 had IB disease, 33 had IIA disease, 87 had IIB disease,
94 had IIIA disease, and 29 had IIIB disease.
The sites of N2 lymph nodes were grouped as follows: upper
mediastinal (highest mediastinal nodes, paratracheal nodes, pretra-
cheal nodes, anterior mediastinal nodes, posterior mediastinal
nodes, tracheobronchial angle nodes, Botallo’s nodes, para-aortic
nodes, and ascending aortic nodes), and lower mediastinal (station
7, subcarinal nodes; station 8, paraesophageal nodes; and station 9,
pulmonary ligament nodes) lymph nodes.2,3 The N1 lymph nodes
comprised hilar (station 10, main bronchus nodes; and station 11,
interlobar nodes), and intralobar (lobar bronchial nodes, segmental
bronchial nodes, and intrapulmonary nodes) ones. Mediastinal
metastasis was considered as “skip metastasis” if any of the N2
nodes, but no N1 nodes were involved. In patients with a tumor in
the left side, Botallo’s nodes, para-aortic nodes, and ascending
aortic nodes were invariably removed although removal of pretra-
cheal nodes was optional.
Survivals were calculated by the Kaplan-Meier method, and
differences in survival were determined by log-rank analysis. Zero
time was the date of pulmonary resection, and the terminal event
was death attributable to cancer, noncancerous cause, or unknown
causes.
Results
Lymph node involvement was recognized in 214 (35.4%) of
the 604 patients evaluated; of them 127 patients (21.0%)
showed N1 node involvement and 87 (14.4%) showed N2
node involvement. Among 127 patients with N1 disease, 54
had metastasis of intralobar nodes but not hilar nodes. In
addition, patients with hilar N1 node metastases were fur-
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 57) main bronchus node (station 10) involvement. The
spread patterns of N2 lymph node metastases according to
the side of the primary tumor are presented in Table 1. Of
44 patients with a right tumor involving the N2 region, 5
(11.3%) had skip metastases, all of which were limited to
station 7. On the other hand, among 43 patients with a left
tumor involving the N2 region, 14 (32.6%) had skip metas-
tases, of whom 9 showed involvement of any N2 node
except station 7. To our surprise, skip metastasis to the
upper mediastinal node but not the lower mediastinal nodes
was found in only 1 patient, who had a bronchioloalveolar
cancer 80 mm in diameter as the primary lesion, with node
station 5 metastasis. Except for that patient, all the patients
with nodal involvement reaching the upper mediastinum
showed involvement of N1 nodes.
Follow-up ranged from 3 to 203 months, with a median
of 92 months for surviving patients. The overall 5-year
survivals of patients with N0, N1, and N2 disease were
71.0%, 50.8%, and 16.7%, respectively (Figure 1). There
were statistically significant differences in survival among
these groups (N0 vs N1 P  .0001, N1 vs N2 P  .0001).
Next, we investigated the survivals of patients with N0, N1,
or N2 disease according to the side of the primary tumor
(Figure 2). Although there were no significant differences in
survival according to the side of the tumor among patients
with N0 or N1 disease, patients with a left N2 tumor had a
worse prognosis than those with a right N2 tumor (P 
.0387). Their 5-year survivals were 6.9% and 28.2%, re-
spectively.
In addition, we examined survivals after classifying pa-
tients with N1 disease into those with and without hilar node
Figure 1. Overall survival curves of patients subjected to com-
plete resection for non–small cell lung cancer according to
pathologic nodal status.(stations 10, 11) metastasis, and patients with N2 disease as
The Journal of Thoracithose with and without upper mediastinal node metastasis.
Overall 5-year survivals of patients with N0, intralobar N1,
hilar N1, lower mediastinal N2, and upper mediastinal N2
disease were 71.0%, 60.1%, 38.8%, 24.8%, and 0%, respec-
tively (Figure 3, A). Significant differences were observed
between intralobar N1 and hilar N1 disease (P  .0489),
Figure 2. Overall survival curves of patients subjected to com-
plete resection for pN0 (A), pN1 (B), and pN2 (C) non–small cell
lung cancer according to side of primary lesion.between hilar N1 and lower mediastinal N2 disease (P 
c and Cardiovascular Surgery ● Volume 129, Number 4 827
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ease (P  .0446), but not between N0 and intralobar N1
disease (P  .1806). Finally, we debated whether the sur-
vivals of patients with nodal involvement up to either sta-
tion 11, station 10, or station 7, differed. The 5-year sur-
vivals were 41.4%, 37.9%, and 37.7%, respectively.
Comparison of the survivals among the three subgroups
demonstrated no significant differences, and their curves
were overlaid (Figure 3, B).
Discussion
Even now, optimal lymph node dissection remains contro-
versial among thoracic surgical oncologists. On the one
hand, lymphadenectomy can improve the accuracy of lung
Figure 3. Overall survival curves of patients subjecte
according to pathologic nodal status. (A) Disease was
disease, lower mediastinal N2 disease, and upper medi
involving up to either interlobar (station 11), main brocancer staging and decrease locoregional recurrence; on the
828 The Journal of Thoracic and Cardiovascular Surgery ● Apriother, it increases operative time, blood loss, and the fre-
quencies of recurrent laryngeal nerve injury, chylothorax,
and bronchopleural fistula. Thus it is important to develop a
more reasonable approach for dissecting mediastinal lymph
nodes.
In this series, we acknowledged so-called skip metastasis
to mediastinal lymph nodes in approximately 22% of our
patients with N2 disease. This percentage is close to those of
previous reports: 27% by Martini and colleagues9 and
28.6% by Ishida and colleagues.10 Skip metastasis may
possibly develop as a result of the existence of lymphatic
channels opening directly to the mediastinum. Subpleural
lymphatics have been reported to have straight passages to
the mediastinal lymph nodes in 22% of the segments in the
complete resection for non–small cell lung cancer
ssified as N0 disease, intralobar N1 disease, hilar N1
al N2 disease. (B) Disease was further classified tumor
s (station 10), or subcarinal (station 7) nodes.d to
cla
astinright lung and in 25% of the segments in the left lung.11
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frequently and at more complicated modes in the left lung
than in the right lung, suggesting that dissection of medi-
astinal lymph nodes on the left side requires more careful
handling. In addition, survival of patients with a right N2
lesion was significantly better than that of patients with a
left N2 lesion, although no significant difference in survival
according to the side of disease was observed in patients
with N0 or N1 disease. Drainage patterns of lymph nodes
and quicker operative access to the right side of mediastinal
lymph nodes may explain restriction of the better survival
results to patients with right-sided lesions. Although para-
tracheal, pretracheal, and tracheobronchial angle nodes can
be dissected through a right thoracotomy without difficulty,
it is hard to reach some of these nodes from the left side.
Moreover although right-sided tumors generally spread to
the ipsilateral mediastinal lymph nodes, tumors in the left
lower lobe are recognized to metastasize passing through
the subcarinal nodes not only to the ipsilateral (left) but also
to the contralateral (right) mediastinum. We should under-
stand the importance of the left side in lymphadenectomy.
Metastatic spread may occur in nonregional mediastinum
without involving lymph nodes of the regional mediasti-
num. Because the extent and the mode of nodal spread are
affected by location of the tumor, we classified the medi-
astinum into an upper region, including the aortic region,
and a lower region. All patients with skip N2 metastasis
from a lower-lobe lesion showed no involvement of upper
mediastinal nodes, except for 1 patient who had a huge
primary tumor. In patients with a lower-lobe tumor without
N1 node involvement, very little prevalence of upper me-
diastinal node involvement can exist. Therefore if N1 nodes
are found to be free of tumor by an adequate use of frozen
sections, upper mediastinal lymphadenectomy is basically
dispensable. An exception is when the patients have ad-
vanced disease suspected on the basis of findings such as
size of tumor and extent of invasion; in such cases complete
hilar and mediastinal lymphadenectomy should be routinely
done as long as the patient is considered able to tolerate the
procedure. In addition, fluorodeoxyglucose positron emis-
sion tomography, reported to be superior to computed to-
mography in assessing lymph node metastasis,12 can help to
decide the extent of lymphadenectomy.
There are ongoing controversies concerning lymph node
stations as a result of the lack of a universally widespread
map. One of the biggest problems is the distinction between
N1 and N2 stations. In general, pleural reflection has been
accepted as an anatomic border between N1 and N2 regions,
as the American Joint Committee established in 1973 and
Mountain1 revised in 1997. Management of nodes around
the main bronchus (stations 7, 10, 11), is the point, because
the main bronchus is positioned partially within the pleural
envelope and partially outside it. Indeed, one of the most
The Journal of Thoraciimportant problems is to decide whether the main bronchus
nodes belong to the N1 or N2 station in relation to prognosis
as well as anatomy. In this study, we found no differences
in survival among patients with nodal metastases up to
either station 11, station 10, or station 7, suggesting that
these nodes could be designated as intermediate between N1
and N2 and that there might be no borderline between N1
and N2 nodes around the main bronchus. Some reports have
also shown the prognoses of patients with hilar N1 disease
and single-station N2 disease to be identical.13,14 Those data
suggest that pleural reflection is not a suitable anatomic
border between N1 and N2 stations in lung cancer.
Another important finding of this study was that patients
with intralobar metastasis had a significantly better progno-
sis than those with hilar metastasis, who in turn had a
significantly better prognosis than those with lower medi-
astinal metastasis. In addition, patients with lower medias-
tinal metastasis had a significantly better prognosis than
those with upper mediastinal metastasis. Upper mediastinal
nodes might be considered as representing an N3 station for
a lower-lobe lesion, although clearer and more extensive
evidence is required. The map for lymph node stations in
lung cancer is still under development. We fervently hope to
have a single, accurate map of lymph node stations that can
be used universally. Otherwise, it will be impossible to
make progress in therapeutic strategies for lung cancer.
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